Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pernix buys Zogenix's controversial pain drug Zohydro ER franchise

Executive Summary

Pernix Therapeutics Holdings Inc. bought Zogenix Inc.’s Zohydro ER (hydrocodone bitartrate capsules) assets for $100mm--$30mm cash, $20mm in Pernix stock (1.68mm shares), and a $50mm six-month promissory note--plus up to $12.5mm in regulatory and $271mm in pre-determined annual sales milestone targets of up to $1bn annually.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Product Purchase
    • R&D and Marketing (Licensing)

Related Companies